Autism Impact Fund II

About Autism Impact Fund II

Autism Impact Fund II invests in seed and Series A companies building AI-enabled solutions for behavioral health, autism care, and complex chronic conditions. Based in New York with offices in San Francisco, Winter Park, and Nashville.

Investment Focus

Location / RegionUnited States

Funding StageSeed

Industry Focus

Ai Ml

Digital Health

Therapeutics

Investor Signals Profile

active

Sweet Spot

Tech-enabled behavioral health founder targeting payer-aligned, outcomes-driven neurodiversity care solutions

neurodiversity

behavioral-health-tech

AI-enabled-care

value-based-care

precision-medicine

Bullish Signals

Fund II first close achieved April 2026 with $150M total AUMblog

Fund I exits validated model: Joshin and Spectrum AI successfully acquiredblog

Thesis expanding to trillion-dollar-plus neurodiversity and behavioral health marketblog

Active portfolio spans Seed to Series C across 15+ companieswebsite

Imagine Pediatrics raises $67M; AIF ecosystem scalingwebsite

Yahoo Finance: AIF autism investments attracting investor noticewebsite

Portfolio active from Seed 2021 through Series B 2025website

Covers blood-test dx, microbiome, precision nutrition, special ed techwebsite

Hosted Autism & Behavioral Health Investment Roundtable Webinarwebsite

New 2025 deals: special ed, caregiver tech, 24/7 care accesswebsite

Deployment spans Seed through Series C; multi-stage activewebsite

Contrarian Signals

Fee-for-service models without value-based care path are explicit non-fitblog

Behavioral health reimbursement risk: politically sensitive, uneven state adoptionblog

Portfolio density in 2021 vintages; newer deals still maturingwebsite

Heavy 2021 cohort; portfolio concentration risk evidentwebsite

Founder Do's

Show clear alignment with value-based care and payer outcomes measurement

Demonstrate AI or data infrastructure connecting diagnosis to personalized treatment

Address co-occurring conditions like ADHD, dyslexia, or anxiety alongside autism

Show a path to measurable cost reduction for payers and health systems

Cover diagnostics, therapeutics, or special education tech for neurodiverse populations

Founder Don'ts

Pitch a pure fee-for-service ABA therapy model with no value-based care path

Position AI as standalone product without data infrastructure backbone

Ignore reimbursement alignment or payer strategy in your pitch

Key GPs & Partners

Christopher Male

Founder & Co-Managing Partner

mission-driventhesis-drivenex-operator

Unlock Investor Signals

$29/month for full signal access. Cancel anytime.

View Plans Browse all Signal Profiles →

Fund Overview

Fund SizeUSD

Saves0

Website

Key People

Chris Male, Robert Sarrazin

Christopher MaleFounder & Co-Managing Partner